Collateral hypersensitivity between ZY19489 and piperaquine neutralizes PfCRT-mediated drug efflux and Plasmodium falciparum resistance

Abstract New antimalarial drugs are needed to combat the current emergence and spread of Plasmodium falciparum parasite resistance to artemisinin-based combination therapies. Here, we characterize ZY19489, a triaminopyrimidine presently in a Phase Ib clinical trial. Asexual blood-stage parasites pre...

詳細記述

書誌詳細

主要な著者:	John Okombo, Tolla Ndiaye, Tarrick Qahash, Igor M. R. Moura, Eva Gil-Iturbe, Laura M. Hagenah, Jessica L. Bridgford, Vinicius Bonatto, Kurt E. Ward, Tomas Yeo, Sunil K. Narwal, Lily V. Orta, Isla Anderson, Satish K. Dhingra, Charisse Flerida A. Pasaje, Heekuk Park, Jonathan Kim, Rafael V. C. Guido, Maria Belén Jiménez-Diaz, Iñigo Angulo-Barturen, Jacquin C. Niles, Filippo Mancia, Anne-Catrin Uhlemann, Sachel Mok, Matthias Quick, Elizabeth A. Winzeler, Didier Leroy, Manuel Llinás, Vandana Thathy, David A. Fidock
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Portfolio 2026-04-01
シリーズ:	Nature Communications
オンライン･アクセス:	https://doi.org/10.1038/s41467-026-70914-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!